Table 1: Socio-demographic and clinical characteristics of study population.
Characteristics |
Haemodialysis N = 13 |
Not on dialysis N = 15 |
Total (%) N = 28 |
Age (year) |
|
|
|
< 40 |
2 |
0 |
2(7.1) |
[40-59] |
6 |
2 |
8(28.6) |
[60-79] |
5 |
12 |
17(60.7) |
≥ 80 |
0 |
1 |
1(3.6) |
Gender |
|
|
|
Male |
8 |
9 |
17(60.7) |
Female |
4 |
7 |
11(39.3) |
Comorbidities |
|
|
|
HTA |
12 |
14 |
26(92.9) |
Diabetes |
4 |
9 |
13(46.4) |
HIV |
1 |
1 |
2(7.1) |
Cirrhosis |
5 |
7 |
12(43) |
Compensated |
4 |
5 |
9(75) |
Decompensated |
1 |
2 |
3(25) |
Baseline nephropathy |
|
|
|
Chronic tubulointerstitial nephritis |
2 |
0 |
2(7.2) |
Ischemic nephropathy |
1 |
2 |
3(10.7) |
Diabetic nephropathy |
0 |
3 |
3(10.7) |
Nephroangiosclerosis |
3 |
1 |
4(14.3) |
Chronic glomerulonephritis |
4 |
3 |
7(25) |
Indeterminate nephropathy |
3 |
6 |
9(32.1) |
HCV therapeutic status |
|
|
|
Naive |
13 |
14 |
27(96.4) |
Relapse (INF-Peg / RBV) |
0 |
1 |
1(3.6) |
Mean duration in haemodialysis (months) |
63.1 ± 37.7 |
/ |
/ |
Virological status at dialysis initiation |
|
|
|
Positive |
1(7.7) |
/ |
/ |
Negative |
10(76.9) |
/ |
/ |
Unknown |
2(15.4) |
/ |
/ |
Median age of HCV diagnosis |
/ |
/ |
6 [3-8.5] |
HTA: Hypertension; HIV: Human Immunodeficiency Virus; INF-Peg: Pegylated interferon; RBV: ribavirin